BioCentury
ARTICLE | Company News

CTIC, Chugai PG-TXL license deal

October 22, 2001 7:00 AM UTC

CTI Technologies, a wholly owned subsidiary of Cell Therapeutics (CTIC), licensed its PG-TXL cancer treatment to Chugai Pharmaceuticals (Tokyo, Japan) for development and commercialization in Asian ma...